Signals flagged in the original
Analyzed by our bias model Full breakdown ↓
The FDA committee has unanimously recommended Moderna's mRNA influenza vaccine for adults aged 50 and over. This marks the first vaccine recommendation by the committee since 2023.
Our neutral summary
The FDA committee has unanimously recommended Moderna's mRNA influenza vaccine for adults aged 50 and over. This marks the first vaccine recommendation by the committee since 2023.
The reporting belongs to NPR — Top Stories; we don't reproduce it.
No note attached
on this article.
Key FDA committee unanimously recommends its first vaccine since 2023
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over